<DOC>
	<DOCNO>NCT02979639</DOCNO>
	<brief_summary>The purpose study evaluate impact reactogenicity GSK Biologicals ' HZ/su vaccine Quality Life ( QoL ) adult ≥ 50 year age .</brief_summary>
	<brief_title>Study Evaluate Impact Reactogenicity Quality Life ( QoL ) , After Administration GlaxoSmithKline ( GSK ) Biologicals ' Candidate Herpes Zoster Subunit ( HZ/su ) Vaccine ( GSK1437173A ) Adults ≥ 50 Years Age</brief_title>
	<detailed_description>The study evaluate impact HZ/su vaccination QoL physical functioning ( PF ) 400 adult ≥ 50 year age ( YOA ) via Patient Reported Outcome questionnaire SF-36 EQ-5D . In addition SF-36 EQ-5D questionnaire , characterization reactogenicity vaccine make diary card data collection .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . Written inform consent obtain subject prior performance study specific procedure . A male female age ≥ 50 YOA time consent . Female subject nonchildbearing potential may enrol study . For study population , nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Any condition , judgment investigator , would make intramuscular ( IM ) injection unsafe . Use plan use investigational nonregistered product ( drug vaccine ) study vaccine current participation plan concurrent participation another clinical study , subject expose investigational noninvestigational product period start 30 day first dose study vaccine study end . Use anticipated use immunosuppressant immunemodifying drug period start 180 day prior study start whole study period . This include chronic administration corticosteroid , longacting immunemodifying agent immunosuppressive/cytotoxic therapy . Inhaled , topical intraarticular corticosteroid allow . Any confirmed suspected immunosuppressive immunodeficient condition result disease immunosuppressive/cytotoxic therapy . Administration immunoglobulins and/or blood product period start 90 day precede first dose study vaccine plan administration study period . Administration plan administration live vaccine period start 30 day first dose study vaccine end 30 day last dose study vaccine , , administration plan administration nonreplicating vaccine period start 15 day prior end 14 day either dose study vaccine . Previous plan administration vaccine HZ study vaccine , entire study period . History HZ . History reaction hypersensitivity likely exacerbate component vaccine . Female plan become pregnant planning discontinue contraceptive precaution . Pregnant lactate female . Significant underlying illness require medication might confound evaluation general/ local AEs , opinion investigator , would expect prevent completion study . Any condition , opinion investigator , might interfere evaluation require study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Herpes Zoster</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Quality life</keyword>
	<keyword>Shingles</keyword>
</DOC>